Article
23.--TREATMENT OF OBESITY
K.A.R. 100-23-1. Treatment of obesity.
A person shall not dispense or prescribe controlled substances to
treat obesity, as defined by this regulation, except in conformity
with the following minimal requirements. (a) Amphetamines shall
not be dispensed or prescribed to treat obesity.
(b) The treating physician shall personally examine the patient.
The physical examination shall include checking the blood pressure
and pulse, examining the heart and lungs, recording weight and height,
and administering any other appropriate diagnostic tests. The examination
and patient history shall determine if controlled substances are
indicated and if any co-morbidity exists. The treating physician
shall enter each of these findings in the patient's record.
(c) The treating physician shall prescribe nutritional counseling,
including behavior modification and appropriate exercise for weight
loss, and record these parameters on the patient record.
(d) The treating physician shall not dispense or prescribe more
than a 30-day supply of controlled substances, at one time, to treat
obesity.
(e) Except as provided by subsection (f) of this regulation, the
treating physician may continuously dispense or prescribe controlled
substances to treat obesity when the physician observes and records
that the patient significantly benefits from the controlled substances
and has no serious adverse effects related to the drug regimen.
A patient significantly benefits from the controlled substances
when weight is reduced, or when weight loss is maintained and any
existing co-morbidity is reduced. At the time of each return visit,
the treating physician shall monitor progress of the patient; the
treating physician or a person acting at the treating physician's
order shall check the patient's weight, blood pressure, pulse, heart,
and lungs. The findings shall be entered in the patient's record.
(f) The treating physician shall not dispense or prescribe additional
controlled substances to treat obesity for a patient who has not
achieved weight loss of at least 5% of the patient's initial weight,
during the initial 90 days of treatment using controlled substances
to treat obesity.
(g) As used in this regulation, the term "controlled substance"
means any drug included in any schedule of the Kansas uniform controlled
substances act.
(h) As used in this regulation, the term "obesity" means a documented
diagnosis of excess adipose tissue, resulting in a body mass index
of 30 or higher (BMI 30kg/mē), or a body mass index of 27 or higher
in the presence of other risk factors (BMI 27kg/mē). Body mass index
is calculated by dividing measured body weight in kilograms by body
height in meters squared (kg/mē); expected body mass index is 20-25
kg/mē. (Authorized by and implementing K.S.A. 65-2837a; effective,
T-86-25, July 24, 1985; effective May 1, 1986; amended, T-100-12-16-96,
Dec. 16, 1996; amended May 9, 1997; amended, T-100-10-30-97, Oct.
30, 1997; amended March 20, 1998.)
|